Cost-effectiveness analysis of extended thromboprophylaxis with rivaroxaban versus no prophylaxis in high-risk patients after hospitalisation for COVID-19: an economic modelling study

BACKGROUND: In patients at high risk of thromboembolism who were discharged after hospitalisation due to COVID-19, thromboprophylaxis with rivaroxaban 10 mg/day for 35 days significantly improved clinical outcomes, reducing thrombotic events compared with no post-discharge anticoagulation. The prese...

Descripción completa

Detalles Bibliográficos
Autores principales: Carvalho de Oliveira, Caroline Cândida, Agati, Leandro Barile, Ribeiro, Camilla Moreira, Resende Aguiar, Valéria Cristina, Caffaro, Roberto Augusto, da Silva Santos, Marisa, Alves Fernandes, Ricardo Ribeiro, Alberto da Silva Magliano, Carlos, Tafur, Alfonso, Spyropoulos, Alex C., Lopes, Renato Delascio, Fareed, Jawed, Ramacciotti, Eduardo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10288203/
https://www.ncbi.nlm.nih.gov/pubmed/37366432
http://dx.doi.org/10.1016/j.lana.2023.100543

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10288203/
https://www.ncbi.nlm.nih.gov/pubmed/37366432
http://dx.doi.org/10.1016/j.lana.2023.100543

Ejemplares similares